Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Sankyo Benicar Offers No Significant Advantage Over Other ARBs, FDA Says

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Sankyo’s antihypertensive Benicar (olmesartan medoxomil) may not offer significant benefits over the other six approved angiotensin II receptor blockers, FDA said in review documents for the NDA.

You may also be interested in...

Sankyo Benicar HCT approved

Sankyo's Benicar HCT (olmesartan/hydrochlorothiazide) will be available in second half 2003. FDA cleared the combination of Sankyo's angiotensin II receptor blocker Benicar and HCTZ June 5 for second-line treatment of hypertension. FDA's Benicar review suggested that the ARB is similar to other agents in the class (1Pharmaceutical Approvals Monthly Sept. 1, 2002, p. 35). Benicar HCT will be available in three fixed-dose combinations: 20 mg olmesartan/12.5 mg HCTZ, 40 mg/12.5 mg and 40 mg/25 m

FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011

Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011

Provenge Paradox Sparks New Thinking About Immunotherapy Trials, Clinical Care

The paradoxical finding that Dendreon's cancer immunotherapeutic Provenge (sipuleucel-T) improved overall survival in men with metastatic castration-resistant prostate cancer but did not appear to slow the progression of the disease is raising questions about the future of clinical development for the burgeoning class





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts